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Abstract
Background: The aim of this study was to investigate the optimal exhaled sevoﬂurane concentration that produces adequate
endotracheal intubation conditions when sevoﬂurane is combined with the different bolus doses of remifentanil used in clinical
practice.
Methods: The patients were randomized to 3 groups (groups 1.0, 1.5, and 2.0), receiving remifentanil bolus doses of 1.0, 1.5, and
2.0mg/kg, respectively. For each group, the concentration of sevoﬂurane used for each consecutive patient was increased or
decreased using the “up-and-down” method based on the success or failure to achieve adequate conditions for intubation in the
previous patient. The remifentanil bolus dose was administered 90 s before intubation and after the target sevoﬂurane concentration
was achieved.
Results: In groups 1.0, 1.5, and 2.0, the effective concentration in 50% (EC50) of the sevoﬂurane concentration required to perform
successful intubation was 3.0, 2.0, and 1.29 vol% and the effective concentration in 95% was 3.45, 2.91, and 1.89 vol%,
respectively. When sevoﬂurane was administered for the induction, the increase in heart rate (HR) of group 1.0 was the highest
among the groups. The highest number of adverse events occurred in group 2.0, including vocal cord rigidity, hypotension, and
bradycardia.
Discussion: The EC50 of the sevoﬂurane concentration was 3.0, 2.0, and 1.29 vol% when it was combined with a bolus dose of
remifentanil of 1.0, 1.5, and 2.0mg/kg, respectively. Of the 3 different bolus doses of remifentanil, the dose of 1.5mg/kg was least
associated with changes in the HR/mean blood pressure during intubation without increasing adverse effects.
Abbreviations: ANOVA = analysis of variance, ASA = American Society of Anesthesiologists, EC50 = effective concentration in
50%, EC95 = effective concentration in 95%, HR = heart rate, MBP = mean blood pressure, PAVA = pooled adjacent violators
algorithm.
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Remarkable development and improvement have been made in
the safety and efﬁcacy of neuromuscular blocking agents.
Currently, neuromuscular blockade can be performed more
safely and with greater comfort when endotracheal intubation or
general anesthesia is performed.Editor: Kazuo Hanaoka.
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1However, in circumstances such as surgery of very short
duration, a rapid return of spontaneous ventilation is required. In
addition, neuromuscular blockade in patients with respiratory
failure or neuromuscular transmission disorders can be danger-
ous when complete reversal fails. In these situations, general
anesthesia without using neuromuscular blocking agents can be
beneﬁcial. Although the new agent sugammadex may provide
efﬁcacy in this situation by rapid elimination of the remnant
neuromuscular blockade,[1] the cost and the insufﬁcient number
of clinical trials of this new agent may prevent its routine use as
well as several reported adverse effects.[2–4] Therefore, several
attempts have been made to develop techniques to perform
endotracheal intubation without neuromuscular blockade. A
number of studies have shown that remifentanil, sevoﬂurane, or
both agents in combination may provide adequate conditions for
laryngoscopy and tracheal intubation in this situation.[5–7]
However, there is little number of studies which have measured
the optimal concentration of sevoﬂurane for performing
intubation without neuromuscular blockade.
When remifentanil is used in combinationwith sevoﬂurane, the
drugs can act additively or synergistically on several measures.[8]
However, to our knowledge, no studies have identiﬁed the
effective dose of sevoﬂurane in combination with different
clinically used bolus doses of remifentanil to obtain adequate
endotracheal intubation conditions without neuromuscular
Table 1
Assessment of intubating conditions.
Score
Parameters 1 2 3 4
Jaw relaxation Complete Slight tone Stiff Rigid
Goo et al. Medicine (2017) 96:9 Medicineblockade. The aim of this study was to investigate the optimal
exhaled sevoﬂurane concentration that produces adequate
conditions for endotracheal intubation without neuromuscular
blockade when sevoﬂurane is combined with the different bolus
doses of remifentanil commonly used in clinical practice.Ease of laryngoscopy Easy Fair Difﬁcult Impossible
Vocal cord position Open Moving Closing Closed
Coughing None Slight Moderate Severe
Intubating conditions were considered as successful if the sum of scores for each parameter was 4. If
the sum of scores was >4, intubation conditions were considered a failure.2. Methods
This study was approved by the Institutional Review Board of the
Armed Forces Medical Command (Seongnam, Korea, approval
no.AFMC-15036-IRB-15-007) and registeredonclinicaltrials.gov
(identiﬁer: NCT02440204). After they provided written informed
consent, male patients aged 18 to 30 years with American Society
of Anesthesiologists (ASA) physical status I whowere scheduled to
undergo elective otolaryngological surgery were enrolled in the
study. Exclusion criteria were a history of reactive airway disease,
smoking, signs predictive of difﬁcult intubation, and a body mass
index≥30 or 15kg/m2. The patients were randomized to 3
groups (groups 1.0, 1.5, and 2.0), according to a computer-
generated randomization table, to receive remifentanil bolus doses
of 1.0, 1.5, or 2.0mg/kg, respectively.
Two anesthesiologists participated in the induction procedure.
One, whowas not blinded to the patient’s group or target exhaled
sevoﬂurane concentration, recorded the data and adjusted the
dose of sevoﬂurane and remifentanil. The other anesthesiologist,
who was blinded, performed the mask ventilation and endotra-
cheal intubation. Patients were premedicated with glycopyrrolate
0.2mg intravenously. An 18-gauge intravenous catheter was
inserted and 0.9% normal saline was infused. In the operating
room, all patients were monitored with electrocardiography,
pulse oximetry, noninvasive blood pressure measurement, and
both inspired and end-tidal concentrations of oxygen, carbon
dioxide, and sevoﬂurane were measured. For each patients, we
used Gas Man (Version 4.2; MedMan Simulations Inc, Chestnut
Hill, MA) software for simulation of sevoﬂurane transmission to
the target organ (brain). On multiple simulations using various
conditions, we discovered that if we maintained the end-tidal
alveolar sevoﬂurane concentration similar to the target concen-
tration over 350 s, equilibrium of the alveolar and vessel-rich
organ (brain) concentrations could be achieved. Therefore,
induction sequence was set as below.
After preoxygenation for 3min, anesthesia was induced using a
face mask with an anesthetic circuit (Primus, Dräger Korea Co.
Ltd, Seoul, Korea) preﬁlled with 8% sevoﬂurane. The fresh gas
ﬂow was set at 6L/min and FiO2 was set at 1.0. At ﬁrst, patients
were left to breathe spontaneously. However, when the tidal
volume was too small (<500 mL) to provide adequate end-tidal
sampling for measurement of expiratory gas concentration or the
end-tidal carbon dioxide level was above 40 mm Hg, ventilation
was assisted. If the patient’s spontaneous ventilation disappeared,
mechanical ventilation was started with a tidal volume of 10mL/
kg, and the respiratory rate was adjusted to maintain an end-tidal
carbon dioxide level between 35 and 40 mm Hg. When the
patient lost consciousness and the end-tidal sevoﬂurane level was
higher than the preselected target concentration, the sevoﬂurane
vaporizer dial was set to 0 until the end-tidal concentration
became similar to the preselected target end-tidal sevoﬂurane
concentration. Then, the inspired concentration was adjusted to
be within a range of 1.0 to 1.4 times the preselected sevoﬂurane
level to identify a concentration that could maintain the
preselected target end-tidal sevoﬂurane concentration steady
for at least 3min. This steady-state end-tidal sevoﬂurane
concentration was maintained for 1min. If the steady-state2concentration was established in<3min, the remaining period of
the 3min was added to the steady-state maintenance time. After
conﬁrmation of the steady state, the bolus dose of remifentanil
according to the preselected group was administered via
intravenous line over 60 s to prevent chest wall rigidity.
Endotracheal intubation was performed 90 s after the end of
the remifentanil bolus administration using a 7.5mm (internal
diameter) reinforced endotracheal tube. If the conditions were
not good enough to perform intubation because of limited mouth
opening or rigid vocal cords, the anesthesia was deepened by
increasing the inspired sevoﬂurane concentration, and rocuro-
nium 0.6mg/kg was used to facilitate intubation.
The concentration of sevoﬂurane used for each patient was
determined by the response of the previously tested patient using
themodiﬁedDixon up-and-downmethod.[9] The ﬁrst patient was
tested at an end-tidal sevoﬂurane concentration of 2.5 vol%,
which was previously determined as the concentration required
for acceptable intubating conditions.[7] Intubation conditions
were scored according to the scoring system described by Helbo-
Hansen et al[10] (Table 1). Intubation was deﬁned as successful
only when the sum of the scores for each parameter was 4 using
this scoring system. When the sum of scores was more than 4, it
was considered a failure. If intubation failed, the target
concentration of sevoﬂurane for the next patient was increased
by 0.5 vol%. If intubation was successful, it was decreased by 0.5
vol%. The cases were collected until 7 pairs of consecutive up-
and-down adjustments of the sevoﬂurane concentration were
achieved.[5,7]
Mean blood pressure (MBP), heart rate (HR), and oxygen
saturation were recorded at initiation, before remifentanil
administration, after remifentanil administration, before intuba-
tion, after intubation, and 1, 2, and 5min after intubation. The
intubation score and any incidences of adverse effects were also
recorded.2.1. Statistical analysis
Statistical analyses were performed using the statistical package
R (version 3.2.0) for isotonic regression and SAS (version 9.2;
SAS Institute, Cary, NC) for the linear mixed model and analysis
of variance (ANOVA). Data are reported as mean± standard
deviation. The sample size was determined to achieve 7 pairs of
failure–success to provide the half effective minimum alveolar
sevoﬂurane concentration. To calculate the regression models
allowing the prediction of the effective concentration of
sevoﬂurane for successful intubation in 50% (EC50) and 95%
(EC95) of the patients, an isotonic regression using the pooled
adjacent violators algorithm (PAVA) was performed for each
group. A bootstrapping approach to produce 83% and 95%
conﬁdence interval was used for the estimates of EC50 and E95.
ANOVA and a linear mixed model were used to analyze the
Table 2
Demographic data of patients in each group.
Group 1.0 (n=22) 1.5 (n=24) 2.0 (n=22) P
Age 21.3±1.7 21.3±1.6 21.5±2.2 0.94
Height, cm 175.4±5.6 175.6±4.2 177.0±6.0 0.60
Weight, kg 72.1±9.4 71.7±10.8 72.1±9.0 0.84
BMI, kg/m2 23.5±3.2 24.3±3.2 23.0±2.5 0.94
Values are expressed as mean± standard deviation.
1.0= remifentanil bolus dose 1.0mg/kg, 1.5= remifentanil bolus dose 1.5mg/kg, 2.0= remifentanil
bolus dose 2.0mg/kg, BMI=body mass index.
Goo et al. Medicine (2017) 96:9 www.md-journal.comdemographic proﬁles and hemodynamic data changes in each
group. A P value <0.05 was considered signiﬁcant.Figure 1. Response crossover plots of the sevoﬂurane alveolar concentration
associated with successful or failed intubation. The starting doses in all groups
were 2.5 vol%, and incremental change was 0.5 vol%. Open circles indicate
failure of intubation and closed circles indicate successful intubation. 1.0=
remifentanil bolus dose 1.0mg/kg, 1.5= remifentanil bolus dose 1.5mg/kg,3. Results
Sixty-eight ASA class I patients participated in this study. To
obtain 7 response crossovers in each group, 22, 24, and 22
patients were recruited to groups 1.0, 1.5, and 2.0, respectively.
There were no statistically signiﬁcant differences in the
demographics of the patients in each group (Table 2). There
were 1, 1, and 3 patients who required neuromuscular blockade
for successful tracheal intubation in groups 1.0, 1.5, and 2.0,
respectively. The other patients were intubated without neuro-
muscular blockade. The response crossover plots of the
sevoﬂurane alveolar concentration associated with successful
or failed intubation are shown in Fig. 1. By isotonic regression
with PAVA and the bootstrap method, there were signiﬁcant
differences in the EC50 and EC95 of each group (Table 3).
We used a linear mixedmodel for analysis of HR andMBP.We
calculated the estimated least-square means at each time (Fig. 2).
There were no signiﬁcant differences between groups in the initial
MBP and HR. In every group, the MBP gradually decreased until
intubation and increased when intubation was performed.
However, theHRwas elevated after induction.When sevoﬂurane
was administered for the induction, the increase in HR of group
1.0 was signiﬁcantly higher than in the other groups (P=0.014).
The HR also decreased when remifentanil was administered and
increased after intubation in every group.
There were 3 adverse cardiac events in group 2.0, including 2
patients with bradycardia and 1 patient who had arrhythmia that
was successfully managed with 0.5mg atropine injection. Three
patients in group 2.0 required rocuronium injection because of
closed vocal cords before intubation. One patient in group 1.5
had bradycardia, and closed vocal cords were encountered in 1
patient in each of groups 1.0 and 1.5.2.0= remifentanil bolus dose 2.0mg/kg.
4. Discussion
The results of this study showed that the concentration of
sevoﬂurane required to perform intubation without neuromuscu-
lar blockade decreased as the bolus dose of remifentanil increased.Table 3
EC50 and EC95 for successful intubation.
Group 1.0 1.5 2.0
EC50 (95% CI) 3.00 (2.36, 3.18) 2.00 (1.38, 2.54) 1.29 (1.14, 1.50)
EC95 (95% CI) 3.45 (3.00, 3.47) 2.91 (2.35, 2.95) 1.89 (1.47, 1.95)
1.0= remifentanil bolus dose 1.0mg/kg, 1.5= remifentanil bolus dose 1.5mg/kg, 2.0= remifentanil
bolus dose 2.0mg/kg, CI= conﬁdence interval, EC50 = effective concentration in 50%, EC95 =
effective concentration in 95%.
3A number of studies have investigated the combination of
remifentanil and propofol for performing intubation without
neuromuscular blockade.[6,11,12] However, other studies showed
that compared with propofol, sevoﬂurane seems to be a better
agent when used as a sole induction agent to perform intubation
without neuromuscular blockade.[13,14] Nevertheless, reports of
the side effects of using high concentrations of sevoﬂurane make
anesthesiologists hesitant to use it as a sole induction agent.[15–17]
In an attempt to lower the required sevoﬂurane alveolar
concentration, intubation without neuromuscular blockade using
remifentanil and sevoﬂurane has been tried.[5,7,14] However, few
studies have investigated the effective end-expiratory alveolar
Figure 2. Intraoperative changes in mean blood pressure and heart rate.
Closed circles indicate group 1.0, open circles indicate group 1.5, and closed
triangles indicate group 2.0. The mean values used in this ﬁgure are the
calculated least-square means. 1.0= remifentanil bolus dose 1.0mg/kg, 1.5=
remifentanil bolus dose 1.5mg/kg, 1min=1 min after intubation performed,
2.0= remifentanil bolus dose 2.0mg/kg, 2min=2min after intubation per-
formed, 5min=5min after intubation performed, Intu= intubation performed.
Goo et al. Medicine (2017) 96:9 Medicineconcentration of sevoﬂurane in combination with different doses
of remifentanil.
It is more feasible to estimate the concentration of inhalation
agents than intravenous agents, by monitoring the exhaled
concentration during surgery and anesthesia. Therefore, in
clinical settings it would be more useful to adjust the sevoﬂurane
concentration during induction rather than to adjust the dose of
remifentanil to achieve effective concentrations of both agents for
intubation.
Unlike studies that attempted to identify the effective dose of
sevoﬂurane in combination with different bolus doses of
remifentanil,[7,8] this study controlled the participants’ age and
general condition within a very narrow range. Only ASA class I
patients aged 19 to 28 years participated in this study. Because
the required doses of both inhalation and intravenous agents are
sensitively affected by the patient’s age and general condition, our
study provides relatively reliable data because of the tightly
controlled age and general condition of the patients.
The results of this study demonstrated that as the bolus dose of
remifentanil increased, the minimal required alveolar concentra-
tion of sevoﬂurane to achieve adequate intubation conditions
could be decreased. The other studies that have described additive
or synergistic effects of the remifentanil–sevoﬂurane combination
support the results of this study.[7,8]4We studied 3 different bolus doses of remifentanil in
combination with sevoﬂurane inhalation. Of these 3 doses,
1.0mg/kg was associated with a requirement for an increase in
sevoﬂurane concentration. According to Cros et al, acceptable
intubating conditions were achieved 2min after using sevoﬂurane
at a concentration of 2.5±0.7 vol% with remifentanil 1mg/kg
injected for 60 s followed by an infusion of 0.25mg/kg per min.
The results of our study showed that the concentration required
to perform intubation while using 1 remifentanil 1mg/kg bolus
was higher than this. The absence of the subsequent remifentanil
infusion and the relatively young age of the patients in our study
might explain these differences.
Unlike the other groups, there was a signiﬁcant increase in HR
after administration of inhalation agents in group 1.0. Sevo-
ﬂurane has been regarded as an agent that does not cause an
increase in HR during induction compared with other inhalation
agents.[18,19] However, several reports describe an elevation in
HRwhen using sevoﬂurane at high concentrations.[20,21] Because
the concentration required to perform intubation was highest in
group 1.0, the results of this study might support those of
previous studies.
By contrast, a remifentanil dose of 2.0mg/kg was associated
with decreased HR and MBP and a lower required dose of
sevoﬂurane. Despite the lowest concentration of sevoﬂurane
being used in group 2.0 in our study, the greatest number of
hypotension or bradycardia events was encountered in this
group. Several studies have reported the incidence of hypotension
and bradycardia after remifentanil use, which may explain our
results.[22,23] In addition, there were 3 patients in group 2.0 who
had closed vocal cords during the induction period. This seems to
be related to the muscle rigidity following a high dose of
remifentanil.[24,25] Interestingly, all 3 of the patients who had
closed vocal cords had received <1% of the target sevoﬂurane
concentration. Although further studies may be necessary to
obtain more reliable data, it seems that sevoﬂurane may have a
role in preventing the remifentanil-induced muscle rigidity
because of its own muscle-relaxant property or by other
mechanisms.
Compared with the other doses, the bolus dose of 1.5mg/kg of
remifentanil was least associated with HR and MBP changes
during the induction period. Changes in MBP or HR during
anesthesia can cause an increase in cardiac workload or impaired
tissue/organ perfusion. These changes can be devastating to those
patients who are vulnerable to these changes. Therefore, it
appears that, compared with the other doses, maintenance of
alveolar sevoﬂurane at 2.25 vol% followed by a bolus dose of
1.5mg/kg remifentanil may provide good intubating conditions
without increasing the risk of side effects when we perform
general anesthesia without neuromuscular blockade.
In this study, we used Gas Man (Version 4.2; Med Man
Simulations Inc) software for simulation of sevoﬂurane trans-
mission to the target organ (brain). By using this simulation, it
took 9 to 12 min to reach steady state between target organ and
inspiration concentration when sevoﬂurane inspiration concen-
tration was kept constant during induction period. However,
when steady alveolar concentration was kept constant, it could be
lowered within 6 min.[26] In the present study, we have used
anesthetic circuit preﬁlled with 8% sevoﬂurane in that we could
reduce time to reach target alveolar concentration. After we
reached target sevoﬂurane concentration, we maintained the
concentration for 390 s (180s for precise adjustment + 60 s for
conﬁrmation, 60 s for remifentanil infusion, and 90 s before
intubation). Therefore, we could get sevoﬂurane concentration
[8] Heyse B, Proost JH, Hannivoort LN, et al. A response surface model
Goo et al. Medicine (2017) 96:9 www.md-journal.comsimilar to the target organ concentration before intubation.
During induction with inhalation agent, conﬁrmation of target
organ concentration is not very feasible. However, because
induction method of this study was designed to achieve target
organ concentration as soon as possible, we hope it could
contribute to further studies using inhalation agents during
induction period.
This study has several limitations. Though we simulated that
the brain concentration of sevoﬂurane could be obtained in 390 s
using our method, more accurate brain concentration could be
achieved if we were able to maintain the concentration for a
longer period of time. However, applying sevoﬂurane for a longer
period of time was not feasible in clinical practice. Furthermore, it
was also important to present a feasible model to obtain the target
sevoﬂurane concentration in the brain during the induction
period which is easy to apply in actual clinical practice. In
addition, because we only included male patients aged 18 to 30
years with ASA physical status I in this study, it is uncertain
whether these results could be appropriately generalized to
patients of other ages and with comorbidities. However, we
believe that result of this study provides good reference data for
further studies.
In conclusion, the EC50 of the exhaled sevoﬂurane concentra-
tion was 3.0, 2.0, and 1.29 vol% when combined with bolus
doses of remifentanil of 1.0, 1.5, and 2.0mg/kg, respectively. Of
the 3 different bolus doses of remifentanil, the bolus dose of 1.5m
g/kg was least related to changes in HR and MBP during
intubation without increasing adverse effects.References
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